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Mutations in ﬁbroblast growth factor receptors (FGFRs) cause human birth defect syndromes and are associ-
ated with a variety of cancers. Although forced expression of mutant activated FGFRs has been shown to
oncogenically transform some immortal cell types, their activity in primary cells remains unclear. Here, we
show that birth defect and cancer-associated FGFR2 mutants promote DNA-damage signaling and p53-
dependent senescence in primary mouse and human cells. Senescence promoted by FGFR mutants was
associated with downregulation of c-Myc and forced expression of c-Myc facilitated senescence escape.
Whereas c-Myc expression facilitated senescence bypass, mutant FGFR2 signaling suppressed
c-Myc-dependent apoptosis and led to oncogenic transformation. Cells transformed by coexpression of a
constitutively activated FGFR2 mutant plus c-Myc appeared to be become highly addicted to FGFR-
dependent prosurvival activities, as small molecule inhibition of FGFR signaling resulted in robust p53-
dependent apoptosis. Our data suggest that senescence-promoting activities of mutant FGFRs may normally
limit their oncogenic potential and may be relevant to their ability to disrupt morphogenesis and cause birth
defects. Our results also raise the possibility that cancers originating through a combination of constitutive
FGFR activation and deregulated Myc expression may be particularly sensitive to small molecule inhibitors of
FGF receptors.
INTRODUCTION
Fibroblast growth factor signaling plays crucial roles during
embryonic development by regulating cell proliferation,
differentiation, survival, cell–cell communication and cell
fate speciﬁcation. The biological effects of FGF ligands are
mediated by binding to FGF receptors, which induce receptor
dimerization, autophosphorylation and the assembly of signal-
ing complexes. Fibroblast growth factor receptor (FGFR) acti-
vation initiates several different phosphorylation cascades
whose combined actions dictate their effects on cell behavior.
Signaling pathways controlled by FGFs include the phospho-
lipase C-gamma (PLC-g), phosphatidylinositol-3 kinase
(PI3K) and Ras/mitogen-activated protein kinase (MAPK)
pathways (1). The strength, anatomical location and duration
of FGF signaling are of critical importance during embryonic
development and mutations in FGFRs that either cause
constitutive FGFR activation, altered receptor dimerization
or inﬂuence ligand-binding speciﬁcity or afﬁnity, can lead to
a variety of birth defects (2,3).
In addition to causing developmental defects, activating or
gain-of-function mutations in FGFRs are found sporadically
inanumberofdifferenttypesofcancer.Forexample,mutations
in FGFR2 are found in endometrial and gastric tumors (4–7),
mutations in FGFR3 are found in urothelial carcinomas (8)
and multiple myeloma (9,10), and mutations in FGFR1 have
been found in glioblastoma (11). Mutations in FGFR3 are
also found in benign epidermal nevi and seborrheic keratoses
(12–14) and single nucleotide polymorphisms in the FGFR2
gene that lead to increased FGFR2 transcription are associated
with increased risk of breast cancer (15–17). In addition to
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FGFR2 (18), is associated with several different cancers.
Consistent with direct participation in tumorigenesis, a
number of studies have shown that expression of
cancer-associated FGFR3 and FGFR2 mutations can
promote oncogenic transformation of immortal mouse cell
lines (7,19–22). However, their effects in both immortal and
primary cells appear to be highly cell type speciﬁc and
proliferation of some cell types is strongly inhibited by
FGFR signaling (reviewed in 1,23). Although the mechanisms
responsible for the different responses that cells have to
mutant FGFRs remain unclear, it has been postulated to be
related to their ability to engage signaling pathways that can
both promote proliferation and suppress proliferation, as
well as by triggering negative feedback mechanisms (1).
Although FGF receptors can activate different signal trans-
duction pathways, the Ras/Raf/MAPK pathway appears to be
of critical importance in mediating the effects of activated
FGF receptors. For example, it was recently shown that
small molecule-mediated suppression of Ras/MAPK signaling
rescued craniosynostosis in a mouse model of Apert syndrome
(24), a disease caused by mutations in FGFR2 that result in
broadened ligand-binding speciﬁcity and increased ligand afﬁ-
nity (25–27). Since the same mutations that cause Apert syn-
drome are also found in some cancers (4–7), it seems likely
that increased Ras/MAPK signaling plays an important role
in their oncogenic activities. However, although activating
mutations in RAS family members and other components of
the RAS/MAPK pathway are frequent events in cancer, their
expression in at least some primary cell types induces senes-
cence (28–30). Similarly, the PI3K pathway, a major
pathway activated by FGFRs, has been demonstrated to
promote senescence when hyperactivated (31). While senes-
cence appears to be triggered by multiple mechanisms,
recent evidence indicates that senescence induced by mutant
Ras and several other oncogenic proteins is associated with
the development of DNA strand breaks that may arise due to
defects in DNA replication (32,33). The induction of senes-
cence and/or apoptosis by oncogenic proteins is associated
with chronic activation of DNA-damage signaling that nor-
mally functions to arrest cell proliferation and promote
repair. This cellular response to oncogenic proteins appears
to provide a signiﬁcant barrier to further progression towards
a malignant state (reviewed in 34–36).
Here we investigated the potential rolethat senescence might
play in regulating the oncogenic activities of mutant forms of
FGFR2 that are associated with human birth defects and
cancer. We show that gain-of-function and constitutively
active FGFR2 mutants promote DNA-damage signaling and
p53-dependent senescence. Induction of senescence was
linked to downregulation of c-Myc and forced expression of
c-Myc facilitated senescence escape and cooperated with
mutant activated FGFR2 in oncogenic transformation. The
mechanism of oncogenic cooperation between mutant FGFR2
and c-Myc involved both c-Myc-facilitated senescence escape
and protection against c-Myc-dependent apoptosis by FGFR2.
Moreover, cells transformed by the combination of constitu-
tively active FGFR2 and c-Myc become highly addicted to
the prosurvival signaling of the mutant receptor, as these cells
could be effectively eliminated by treatment with small mol-
eculeFGFRinhibitors.Thesestudiesprovideinsightintomech-
anisms underlying the differential effects of mutant FGFRs on
cell proliferation and help deﬁne the properties of mutant
FGFRs that make them highly oncogenic, but also susceptible
to drug-induced cell death.
RESULTS
Birth defect and cancer-associated FGFR2 mutants induce
senescence in primary cells
FGFR2
S252W, a mutation that affects ligand binding and causes
Apert syndrome, and FGFR2
K659E, a predicted constitutively
active receptor mutated in the tyrosine kinase region, have
been identiﬁed in cancers (5–7). The FGFR2
K659E mutation is
equivalent to FGFR3
K650E, which is also found some cancers
and causes the neonatal lethality syndrome Thanatophoric Dys-
plasia Type II (3). Because FGFRs signal through the PI3K and
MAPK pathways, which both promote senescence when hyper-
active, we examined whether FGFR2
S252W and FGFR2
K659E
promoted senescence in primary mouse embryonic ﬁbroblasts
(MEFs). Wild-type FGFR2, FGFR2
S252W and FGFR2
K659E
were introduced into primary MEFs at passage 2–3 using retro-
viral expression vectors, brieﬂy drug selected, then stained for
senescence-associated (sa) b-galactosidase activity. Cells
expressing Ras
G12V were used as positive controls in these
experiments. In contrast to vector alone or wtFGFR2,
expression of the FGFR2 mutants, like Ras
G12V, led to a signiﬁ-
cant increase in the number of cells that stained positive for
sa-b-galactosidase (Fig. 1A and B). sa-b-Galactosidase stain-
ingcorrespondedtotheappearanceofmanyenlargedandmulti-
nucleated cells exhibiting a ﬂattened morphology, and
suppressed cell proliferation (Fig. 1A and C). Similarly,
expression of FGFR2
S252W and FGFR2
K659E in human
IMR90 lung ﬁbroblasts, like Ras
G12V, led to an increase in the
number of sa-b-galactosidase-positive cells (Fig. 1E and F).
A constitutively active FGFR3 mutant (FGFR3
K650E) behaved
essentially identical to FGFR2
K659E in these assays (data not
shown). The induction of senescence observed was associated
with only a moderate increase in levels of the FGFR2 mutants
compared with endogenous FGFR2 in MEFs and IMR90 ﬁbro-
blasts (Fig. 1D and G). These results suggest that although birth
defect and cancer-associated FGFR mutants generally promote
proliferation and oncogenesis in immortal cells, they promote
senescence in primary cells.
Activation of DNA-damage signaling by FGFR2 mutants
We next investigated whether senescence caused by mutant
FGFR2 proteins is related to DNA-damage signaling and acti-
vation of DNA-damage checkpoints that promote cell cycle
arrest. Primary MEFs and IMR90 ﬁbroblasts subjected to ret-
roviral expression of wild-type FGFR2, FGFR2
S252W,
FGFR2
K659E or Ras
G12V at passage 3 were examined for
several proteins that participate in the DNA-damage response
at passage 5. When compared with control cells infected with
empty vector or wild-type FGFR2, expression of either
FGFR2
S252W, FGFR2
K659E or Ras
G12V resulted in an increased
percentage of cells exhibiting the characteristic speckled
pattern of gH2AX (Ser139-phosphorylated H2AX) (Fig. 2A
2610 Human Molecular Genetics, 2009, Vol. 18, No. 14and B), an alternative histone that associates with Ataxia
telangiectasiamutated(ATM)andaccumulatesatDNA-damage
foci (35). IMR90 ﬁbroblasts similarly showed increased
gH2AX staining and gH2AX staining co-localized with
serine 1981-phosphorylated ATM (Fig. 2C–E). Very similar
results were achieved when MEFs and IMR90 ﬁbroblasts
Figure 1. FGFR2 mutants promote senescence in primary cells. (A) Morphology (live cells and tubulin/DAPI stained cells) and sa-b-galactosidase staining of
primary MEFs. (B) The mean percentage of b-galactosidase-positive cells and standard deviation based on three independent experiments. (C) Mean number of
cell counts and standard deviation from passage 5 MEFs plated at 50000 cells per dish (day 0) and counted every 2 days. (D) Western blots showing levels
of FGFR2, phospho-ERK1/2 (T202/Y204) and total ERK in MEFs. (E) Live and sa-b-galactosidase staining of primary human IMR90 ﬁbroblasts expressing
the indicated proteins. (F) Mean percentage of sa-b-galactosidase-positive IMR90 cells and standard deviation based on triplicate samples from three indepen-
dent experiments. (G) Western blot of IMR90 ﬁbroblasts as in (D). Scale bars: live cells and sa-b-gal—50 mM, tubulin/DAPI—10 mM.
Human Molecular Genetics, 2009, Vol. 18, No. 14 2611Figure 2. Induction of DNA-damage response by FGFR2 mutants. (A) gH2AX immunoﬂourescense in primary MEFs expressing the indicated proteins. Low
and higher magniﬁcation views are provided to show both the general increase in the number of cells staining for gH2AX, and the speckled pattern of gH2AX
staining in positive cells. (B) Mean percentage of gH2AX-positive MEFs with standard deviation from three independent experiments. (C) gH2AX and
p(ser1981)-ATM staining in IMR90 cells expressing the same set of proteins as in (A). (D) Mean percentage of gH2AX- and pATM-positive (cells showing
co-localization) IMR90 ﬁbroblasts with standard deviations calculated from three independent experiments. Hydrogen peroxide treated cells were used as a posi-
tive control, and DAPI staining was used to visualize nuclei in these experiments. (E) gH2AX and pATM staining showing coincident staining in IMR90 ﬁbro-
blasts expressing FGFR2
S252W or FGFR2
K569E as indicated. (F) Immunoblot analysis of the indicated proteins. Residues recognized by phospho-speciﬁc
antiserums is indicated. Actin was used as a general loading control. Scale bars: all are 50 mm, except ‘high’ (magniﬁcation) which is 10 mm.
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(Ser25) 53BP1 (Supplementary Material, Fig. S2), a p53 inter-
acting protein activated in response to DNA damage (35).
Further, immunoblot analysis showed increased DNA
damage-associated phosphorylation of Chk2, p53BP1 and
p53 in IMR90 ﬁbroblasts expressing mutant FGF receptors
or Ras (Fig. 2D). In addition, levels of p53, p21 and p16
were increased in these cells (Fig. 2D, also see Fig. 3D), a
result consistent with activation of the DNA-damage check-
point and suppressed proliferation and/or senescence.
Finally, levels of trimethylated (K9) Histone H3, a marker
of silenced (hetero) chromatin, were increased by the
expression of mutant FGF receptors and Ras.
The constitutively active FGFR2
K659E mutant was
generally more effective at inducing DNA-damage foci and
senescence-associated markers than FGFR2
S252W, but not as
effective as oncogenic Ras
G12V (Fig. 2A–D), a result that
generally correlated with their abilities to promote senescence
(Fig. 1).
Senescence induced by mutant FGFRs can be bypassed
by increased Myc or loss of p53
The well-documented role of p53 in senescence (34) and the
apparent activation of p53 and p53 targets associated with
senescence by FGFR2 mutants in IMR90 ﬁbroblasts
(Fig. 2F) and in MEFs (Fig. 3D), suggested that p53 might
be playing a critical role in the senescence observed. To
examine the role of p53, wild-type FGFR2, FGFR2
S252W,
FGFR2
K659E and Ras
G12V were expressed in p53-null MEFs
at passage 5 and cells stained for sa-b-galactosidase activity
at passage 7. As previously reported (28), Ras
G12V-induced
senescence was dependent on p53. Likewise, p53-null MEFs
expressing either FGFR2
S252W or FGFR2
K659E failed to
Figure 3. Suppression of mutant FGFR2-induced senescence by coexpression of c-Myc or loss of p53. (A) sa-b-Galactosidase staining of cells infected with
retroviruses expressing the indicated proteins in wild-type MEFs, p53-null MEFs or MEFs expressing c-Myc. (B) Mean percentage and standard deviation
of sa-b-galactosidase-positive cells for infected wild-type MEFs and MEFs expressing exogenous c-Myc. (C) The average number of population doublings cal-
culated during successive cell passages for the various cell strains expressing c-Myc. Data are from two independent experiments performed in triplicate and
standard deviations are shown. (D) Immunoblot analysis of DNA damage and senescence markers in primary wild-type MEFs and p53-null MEFs expressing
the indicated proteins. Scale bars: 50 mM.
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sa-b-galactosidase activity (Fig. 3A). Consistence with the
abrogated senescence response in p53-null MEFs, p21 and
p16 levels were not increased by mutant FGFRs or oncogenic
Ras (Fig. 3D). p19
ARF levels were elevated in p53-null MEFs
as expected (37) and were further increased through a
p53-independent mechanism by the expression of mutant
FGF receptors or Ras (Fig. 3D).
Another potentially important factor involved in senescence
is c-Myc. c-Myc is required for sustained proliferation of
primary MEFs (38), as well as for susceptibility of ﬁbroblasts
to transformation by Ras (39), and is downregulated during
senescence (40). Indeed, we found c-Myc protein and RNA
levels were downregulated in primary MEFs expressing
FGFR mutants or Ras
G12V (Fig. 3D and data not shown), a
result consistent with the increased sa-b-galactosidase activity
and decreased proliferation observed with these cells. In con-
trast, p53-null MEFs failed to downregulate c-Myc levels in
response to mutant FGFRs or Ras (Fig. 3D).
To examine the role of c-Myc downregulation in mediating
growth arrest and senescence caused by mutant FGFR,
primary MEFs at passage 2 were ﬁrst generated to express
ectopic c-Myc, and subsequently infected with control virus
or viruses expressing wild-type FGFR2, FGFR2 mutants or
Ras
G12V at passage 4. Drug-selected populations were
replated, grown for 5 days and then stained for
sa-b-galactosidase activity. Ectopic c-Myc expression
(Fig. 3D) was found to be effective at reducing the otherwise
elevated number of sa-b-galactosidase-positive cells caused
by the expression of mutant FGFRs or Ras alone (Fig. 3A
and B). Additionally, the sa-b-galactosidase-positive cells
found in these populations generally did not exhibit the
highly enlarged and often multinucleated morphology of
senescent cells (Fig. 3A). Finally, when compared with
vector control cells or cells expressing c-Myc alone, cells
co-expressing c-Myc with either the mutant FGFRs or Ras
showed elevated proliferation during a period when MEFs
typically undergo senescence. However, the proliferated rate
of these cells was reduced compared with pre-senescent wild-
type MEFs (Fig. 3C), suggesting that ectopic Myc only par-
tially overcomes senescence-associated proliferative arrest.
Similar to a previous report (41), forced expression of
c-Myc alone in primary MEFs had an initial toxic effect, as
reﬂected in a reduction in cell number compared with vector
control cells (Fig. 3C), The continued proliferation of cells
expressing c-Myc plus FGFR2 mutants or Ras
G12V indicates
that these proteins at least partially negate Myc-dependent tox-
icity. c-Myc expression in turn appears to facilitate senescence
rescue of MEFs expressing FGFR2 mutants or Ras
G12V by
overriding the effects of p53, p21 and p16, which remain upre-
gulated in these cells (Fig. 3D). However, continued p53
expression in MEFs expressing ectopic c-Myc appears to
play a role in the Myc-dependent toxicity, since little or no
toxicity was observed when c-Myc was overexpressed in
p53-null MEFs (data not shown, also see 41).
Taken together, these results suggest that while c-Myc
expression facilitates escape from growth arrest/senescence
caused by the expression of mutant FGFRs or Ras
G12V,
FGFR2 mutants or Ras
G12V partially rescues p53-dependent
toxicity caused by forced c-Myc expression.
c-Myc and constitutively active FGFR2 cooperate in
oncogenic transformation
The ability of c-Myc to promote escape from mutant
FGFR2-induced senescence raised the possibility that c-Myc
and mutant FGFRs may cooperate in oncogenic transform-
ation. To test this, we ﬁrst performed focus formation
assays. MEFs at passage 5 previously infected with c-Myc ret-
rovirus were infected with virus expressing vector alone, wild-
type FGFR2, FGFR2
K659E or FGFR2
S252W. Infected cells were
plated at equal density and stained with methylene blue two
weeks later. In contrast to vector control and wild-type
FGFR2, MEFs infected with FGFR2
K659E or FGFR2
S252W
both gave rise to dense foci of morphologically transformed
cells. However, FGFR2
K659E was consistently more effective
than FGFR2
S252W in cooperating with c-Myc in these assays
(Fig. 4A and B). Whereas cells transformed with
FGFR2
K659E plus c-Myc formed colonies in soft agar assays
(Fig. 4C) and formed tumors when injected into athymic
mice (4/4), cells expressing FGFR2
S252W plus c-Myc neither
formed colonies in soft agar (Fig. 4C) or formed tumors in
athymic mice (0/4). In addition, when introduced into
primary p53-null MEFs, FGFR2
K659E (and Ras
G12V) was
more effective than FGFR2
S252W or wild-type FGFR2 in
causing morphological transformation, foci formation and
colony-forming ability in soft agar (not shown). Finally, con-
sistent with results showing that c-Myc partially rescued
senescence caused by the FGFR2 mutants, morphologically
transformed cells derived from focus formation assays
showed no indications of senescence and proliferated
continuously for greater than 10 passages at a high rate (not
shown).
The differential abilities of FGFR2
S252W and FGFR2
K659E
to cause malignant transformation in cooperation with
c-Myc, or in the absence of p53, likely reﬂect the different
mechanisms responsible for their activation; whereas
FGFR2
K659E is constitutively active, FGFR2
S252W activation
remains dependent on ligand binding, and FGF ligands may
be limiting in our growth conditions.
Cooperation between constitutively active FGFR2 and
Myc relies on prosurvival activities of the mutant receptor
It is well-established that forced Myc expression can sensitize
cells, particularly primary cells, to apoptosis (reviewed in
42,43). Therefore the ability of FGFR2 mutants to suppress
toxicity caused by ectopic c-Myc expression (Fig. 3C) and
cooperate with Myc in cell transformation (Fig. 4) raised the
possibility that they do this at least in part by suppressing
Myc-dependent apoptosis. To test this, MEFs coexpressing
c-Myc alone or c-Myc plus the FGFR2 mutants, wtFGFR2,
or Ras
G12V were subjected to serum deprivation (0.1% fetal
bovine serum—FBS), conditions in which forced c-Myc
expression causes apoptosis. Simultaneous with serum depri-
vation, cells were treated with the FGFR inhibitor
PD173074 (44) or DMSO vehicle control. Apoptosis was eval-
uated by ﬂuorescence-activated cell sorting (FACS) of cells
stained with AnnexinV antiserum and the DNA intercalator
7-AAD to distinguish early apoptotic cells (AnnnexinV-
positive, 7-AAD-negative) and late apoptotic cells
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FGFR inhibition (DMSO vehicle alone), c-Myc expression
signiﬁcantly increased apoptosis compared to vector-infected
MEFs as expected, and apoptosis was further increased by
suppression of endogenous FGFR signaling with PD173074
(Fig. 5A and C). Expression of wild-type FGFR2 or
FGFR2
S252W provided protection against Myc-dependent
apoptosis that was lost upon treatment with PD173074
(Fig. 5A and C). FGFR2K569E also provided some protection
against c-Myc-dependent apoptosis (that did not reach statisti-
cal signiﬁcance), but strikingly, in the presence of PD173074,
nearly all cells expressing c-Myc and FGFR2
K569E had under-
gone apoptosis within 14 hours of serum deprivation
(Fig. 5A–C). Expression of FGFR2
K569E (or FGFR2
S252W)
had little effect on apoptosis in the absence of ectopic
c-Myc expression (Fig. 5A and data not shown), demonstrat-
ing that the high level of apoptosis that occurs in the presence
of the FGFR2
K569E plus c-Myc is dependent on both the
mutant FGFR and c-Myc. Finally, Ras
G12V provided modest,
but not statistically signiﬁcant, protection against Myc-
dependent apoptosis, and apoptosis was not signiﬁcantly
increased when these cells were treated with PD173074
(Fig. 5A–C). The latter results are consistent with Ras operat-
ing downstream of FGFRs. Moreover, both the MEK inhibitor
PD98059 and the PI3K inhibitor LY294002 were effective at
abrogating the prosurvival activities of Ras
G12V or
FGFR2
K569E in cells that coexpressed ectopic c-Myc (not
shown).
To further investigate the effect of mutant FGFRs on
c-Myc-dependent apoptosis, experiments were repeated
under normal serum levels (10%) using two different concen-
trations of PD173074 (1.25 or 5 mM). MEFs expressing c-Myc
alone showed relatively low levels of apoptosis in the presence
of vehicle (Fig. 5D). wild-type and FGFR2
S252W had a modest,
but not statistically signiﬁcant, protective effect against apop-
tosis that was lost with FGFR inhibition (Fig. 5D). The com-
bination of FGFR2
K569E plus c-Myc exhibited less apoptosis
than c-Myc alone, but treatment with PD173074 induced a
high level of apoptosis (Fig. 5D). FGFR inhibition in MEFs
expressing Ras
G12V plus c-Myc again had little or no effect
on levels of apoptosis (Fig. 5D).
Taken together, these results indicate that mutant hyperac-
tive FGFR2 signaling generally has a protective effect
against Myc-dependent apoptosis and that MEFs oncogeni-
cally transformed by the combination of FGFR2
K569E plus
c-Myc appear to become highly addicted to the prosurvival
activities of the mutant receptor and, as a result, highly suscep-
tible to apoptosis when subjected to FGFR inhibition.
Consistent with the powerful pro-apoptotic effect that
PD173074 had on cells transformed by FGFR2
K659E plus
c-Myc, FGFR signaling was strongly and rapidly suppressed
by PD173074 treatment (2 h) in these cells, as indicated by
the activation state of ERK1/2 and, to a lesser extent, Akt
(Fig. 6). In contrast, PD173074 had only a weak inhibitory
effect on ERK and Akt activation in cells expressing
FGFR2
K659E alone, consistent with the notion that when
expressed together with Myc, cells develop an increased
dependence on the mutant receptor for ERK activation and
survival. PD173074 also had only a weak inhibitory effect
on ERK and Akt activation in cells expressing wtFGFR2 or
Figure 4. Constitutively activated FGFR2 cooperates with Myc in oncogenic transformation. (A) Focus formation assays, (B) live cell morphology and (C)
colony formation assays in soft agar with primary MEFs infected with retroviruses expressing the indicated proteins or combinations of proteins.
Human Molecular Genetics, 2009, Vol. 18, No. 14 2615Figure 5. Prosurvival activity of FGF receptor mutants. (A) MEFs expressing the indicated proteins were subjected to serum deprivation (0.1% FBS) plus DMSO
vehicle or FGFR inhibitor PD173074 for 14 h. Cells were stained with AnnexinV and 7AAD and the percentage of AnnexinV-positive apoptotic cells (right-side
quadrants) and 7AAD stained cells (lysed/dead cells—upper quadrants) determined by FAC sorting. Data shown are representative of at least two independent
experiments performed in triplicate. (B) Live cell images showing the response of the indicated cell lines to serum deprivation with and without PD173074. (C)
Bar graph showing mean percentage of AnnexinV-positive cells present following serum-deprivation and either DMSO vehicle or PD173074.  P , 0.005 and
  P , 0.0005 for the speciﬁc comparisons indicated. Note that the percentage of apoptotic cells observed with the FGFR2
K659E plus c-Myc strain treated with
PD173074 was signiﬁcantly greater than in any of the other cell strains tested in this experimental set. (D) MEFs expressing the indicated proteins grown in 10%
FBS were subjected to DMSO vehicle or FGFR inhibitor PD173074 treatment at either 1.25 or 5 mM and analyzed for apoptosis as described above. The
number of apoptotic cells in the expressing FGFR2
K659E plus c-Myc strain was signiﬁcantly greater (P , 0.0005) than any of the other experimental settings
shown in (D).
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S252W plus c-Myc (Fig. 6), a result consistent with the
low levels of apoptosis induced in these cells. As expected,
phosphorylation of Erk and Akt was not altered by
PD173074 in MEFs expressing Ras
G12V plus c-Myc (Fig. 6).
In addition to inactivation of ERK, the high level of
apoptosis caused by PD173074 treatment of cells expres-
sing FGFR2
K659E plus c-Myc was associated with modestly
increased levels of Puma, a pro-apoptotic protein encoded
by a p53 target gene and lower levels of anti-apoptotic
BclXL protein than in cells expressing either FGFR2
K659E
or c-Myc alone (Fig. 6). Although p53 levels appeared to
not directly correspond to levels of apoptosis, the unique
combination of elevated Puma, low BclXL and loss of ERK
in cells expressing FGFR2
K659E plus c-Myc may contribute
to the high level of apoptosis observed with these cells.
Apoptosis of MEFs transformed by FGFR2
K659E plus
c-Myc triggered by PD173074 is p53-dependent
We next directly tested whether the robust apoptosis caused by
PD173074 treatment of cells expressing FGFR2
K659E plus
c-Myc was p53-dependent. p53-null MEFs were infected
with c-Myc retrovirus, drug selected, then infected with
FGFR2
K659E retrovirus and drug selected. Similar to wild-type
MEFs expressing FGFR2
K659E plus c-Myc, these cells were
capable of forming foci of morphologically transformed
cells and growth in soft agar (data not shown). However, in
contrast to wild-type MEFs transformed by FGFR2
K659E
plus c-Myc, p53-null MEFs transformed by FGFR2
K659E
plus c-Myc showed little or no apoptosis following
PD173074 treatment, either in medium containing 10% FBS
or under serum-deprived conditions (Fig. 7A and B). The
loss of sensitivity to PD173074 in these cells occurred
despite the presence of elevated levels of c-Myc and
FGFR2
K659E (Fig. 7C).
DISCUSSION
Our results further deﬁne the oncogenic activities of mutant
activated FGFRs by showing that they promote
DNA-damage-associated senescence and that events such as
loss of p53 or Myc deregulation suppress their senescence-
promoting activity and promote oncogenic conversion. Pre-
vious studies using immortal and cancer-derived cell lines
indicated that the oncogenic activity of cancer-associated
FGFR mutants is associated with both their ability to
promote cell proliferation and to exert prosurvival activity
(6,7, data not shown). The intrinsic ability of mutant FGFRs
to stimulate cell proliferation, together with our ﬁnding that
they promote DNA-damage signaling, is consistent with
models of oncogene-induced ‘hyperproliferative stress’, in
which excessive proliferation signaling is thought to compro-
mise the integrity of DNA replication and lead to the develop-
ment of DNA strand breaks (45). However, although generally
consistent with this model, it remains to be shown that
hyperproliferation signaling mediated by mutant FGFRs
leads to DNA strand breaks. In addition to DNA-damage sig-
naling, senescence has been linked to several other mechan-
Figure 6. Immunoblot analysis of FGFR signaling in cells treated with PD173074. MEFs expressing the indicated proteins were treated with DMSO vehicle (O)
or a titration of PD173074 (1.25, 2.5, 5 and 10 mM) for 2 h. Cell lysates were analyzed for expression of the indicated proteins. pAKT–pSer473.
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induction of ER stress signaling (46), Sprouty upregulation
and negative feedback signaling in the MAPK pathway (47),
senescence-associated heterochromatin formation (SAHF),
production of reactive oxygen species (ROS) and telomere
erosion (reviewed in 36). Although we cannot rule out that
ROS and telomere erosion may be involved in DNA-damage
signaling and senescence observed in this study, we did
not consistently observe induction of Sprouty or ER stress
markers in MEFs or IMR90 ﬁbroblasts expressing mutant
FGFR2 (data not shown). However, we did observe increased
levels of trimethylated (K9) Histone H3, a potential indication
that SAHF cooperates with, or is a byproduct of activation of
DNA-damage signaling by these oncogenic proteins.
Another mechanism that might contribute to the induction
of senescence is c-Myc downregulation. Senescence induced
by the expression of FGFR2 mutants, as well as Ras
G12V,
led to c-Myc downregulation, and coexpression of Myc with
these proteins facilitated senescence escape. The decreased
levels of c-Myc in primary cells may be an indirect conse-
quence of cells exiting the cell cycle and becoming senescent.
Alternatively, DNA-damage signaling or other signaling
events activated by oncogenic Ras or FGFR2 mutants in
primary cells may serve to more directly downregulate
Figure 7. Apoptosis caused by FGFR inhibition in MEFs expressing exogenous c-Myc and FGFR2
K569E is p53 dependent. (A) Primary MEFs and p53-null
MEFs, both transformed by co-expression of c-Myc and FGFR2
K569E, were treated with DMSO vehicle or 1.25 mM PD173074 in medium containing 10%
FBS or in medium containing 0.1% FBS for 14 h. The percentage of AnnexinV and 7AAD positive cells was determined by FACS analysis. Assays were per-
formed in triplicate and mean percentage of total apoptotic cells with standard deviation are shown in (B).  P , 0.0005 when compared with comparably treated
p53-null MEFs. (C) Western blot showing expression of FGFR2
K569E and c-Myc in the indicated cell lines. The dash indicates endogenous c-Myc and the aster-
isk indicates the slightly smaller human c-Myc protein that was introduced.
2618 Human Molecular Genetics, 2009, Vol. 18, No. 14c-Myc. Since c-Myc is essential for sustained proliferation of
primary ﬁbroblasts (38,48), its downregulation in this setting
likely directly contributes to cell cycle exit and senescence.
Our results therefore raise the possibility that the diminished
or abrogated senescence response typical of immortal and
cancer cells may in part reﬂect the acquisition of oncogenic
events that prevent proper downregulation of Myc. This idea
is consistent with results showing that conditional inactivation
of Myc in tumors triggers senescence (49,50). Moreover, the
ﬁnding that c-Myc levels are elevated in early passage
MEFs lacking p53 (Fig. 3D), raises the possibility that
c-Myc upregulation in this setting constitutes a critical and
perhaps general mechanism underlying senescence escape
and oncogenic progression associated with loss of p53.
Although suppression of mutant FGFR2-induced senes-
cence by exogenous Myc expression appears to be an impor-
tant mechanism contributing to their oncogenic cooperation,
suppression of Myc-driven apoptosis by hyperactive FGFR
signaling may be equally important. A number of different
oncogenic proteins that are strongly mitogenic sensitize cells
to apoptosis, with Myc being the prototypical member of
this group (42,43). Both the mitogenic and pro-apoptotic
activity of Myc is enhanced by constitutive and/or high-level
expression of c-Myc protein, a common feature of tumor
cells. Accordingly, the mitogenic and oncogenic activities of
deregulated Myc expression are linked to events that function
to suppress Myc’s pro-apoptotic activity, such as loss of p53.
Our results suggest that the constitutively active FGFR2
K569E
mutant cooperates with forced Myc expression in oncogenic
transformation in part by suppressing Myc-dependent apopto-
sis. Further, the striking sensitivity of these cells to apoptosis
induced by FGFR inhibition, which was far greater than that
caused by c-Myc expression alone, suggests that they
develop an addiction to the prosurvival activities of the
mutant receptor. Interestingly, the sensitivity of cells expres-
sing FGFR2
K659E plus c-Myc to apoptosis was linked to
robust inactivation of ERK1/2, which did not occur in cells
expressing FGFR2
K569E alone. One possible explanation for
this result is that constitutively active FGF receptor signaling
may be prone to co-op, replace or otherwise downregulate the
activities of overlapping signaling pathways that contribute to
ERK activation and normally provide pro-survival signaling.
Such a tendency would be predicted to make cells more
dependent on the mutant receptor for ERK activation and
associated prosurvival signaling, but would be driven and
manifest only in the presence of strong pro-apoptotic activity,
such as that caused by constitutively high Myc expression.
Although the underlying mechanisms responsible for the
development of oncogene addiction or co-dependency in
general, and in cells expressing Myc and FGFR2K569E in par-
ticular, remain unclear, these cells may offer a useful model
for dissecting this phenomenon.
The combination of FGFR2
K569E and c-Myc created highly
oncogenic cells susceptible to apoptotic elimination by FGFR
inhibition, whereas cells expressing FGFR2
S252W plus c-Myc
were neither tumorigenic nor vulnerable to apoptosis. This
difference in susceptibility is likely due to FGFR2
K569E
being constitutively activated and FGFR2
S252W being largely
dependent on ligand binding. Interestingly, endometrial
tumor cells containing an FGFR2
S252W mutation and gastric
tumors with FGFR2 ampliﬁcation were highly susceptible to
apoptosis when treated with PD173074 (6,7,51). Although it
is not clear why these tumor cells are more sensitive to
FGFR inhibition than MEFs expressing FGFR2
S252W plus
c-Myc, it may be related to cell type-speciﬁc differences in
endogenous levels of FGF ligand(s) that the mutant receptor
requires for full activation. Because aberrant activation of
FGFR2
S252W is related primarily to its broadened ligand-
binding speciﬁcity and increased ligand-binding afﬁnity, its
pathological activities must necessarily be linked to local or
cell-intrinsic ligand levels. Therefore, the ligand-dependent
nature of Apert syndrome mutations, like FGFR2S252W and
FGFR2S253W, together with a requirement for additional coop-
erating events like Myc deregulation or loss of p53 that sup-
press senescence, suggests that their oncogenic potential is
less likely to be realized than constitutively activated mutant
receptors. Moreover, the multiple events needed to elicit onco-
genic activity from FGFR2
S252W may explain why Apert syn-
drome is not associated with a strong predisposition to cancer.
Although it is clear that FGFR inhibition can induce apop-
tosis in cells derived from some tumors containing FGFR2
(and FGFR3) mutations or gene ampliﬁcation (6,7,51), the
underlying mechanism remains unclear. Our results suggest
that their vulnerability is likely dependent on an additional
event(s) that has latent pro-apoptotic activity, such as Myc
deregulation. Interestingly, not all gastric tumor-derived cell
lines containing ampliﬁed FGFR2 respond to FGFR inhibition
by undergoing apoptosis (50). Instead, some respond by
exiting from the cell cycle, a result consistent with the
tumor cells becoming dependent on the proliferation-
associated activities of the mutant or ampliﬁed receptors.
Thus, it might be informative to screen gastric and endo-
metrial tumor cells that have FGFR2 mutations or gene ampli-
ﬁcation for alterations at Myc loci (e.g. gene ampliﬁcation),
and then determine whether their sensitivity to apoptosis
(versus blocked proliferation) by FGFR inhibition is related
to, or dependent on, Myc deregulation. Deﬁning these
relationships may more precisely identify tumors particularly
susceptible to apoptotic elimination by small molecule FGFR
inhibitors.
MATERIALS AND METHODS
Expression plasmids
Retroviral expression plasmids used included
pFBneo-wtFGFR2c (Bek), pFBneo-FGFR2c
K659E, pFBneo-
Ras
G12V, pFBneo-GFP, pLXSN-FGFR2c
S252W, pBABEpuro-
c-Myc, pBABEpuro-H-Ras
G12V. Ecotropic retroviruses were
produced in Ecopack 2 293 cells (Clonetech), and amphotro-
pic retroviruses were generated in Phoenix cells following
the manufacturers’ protocols.
Cells, cell culture and retroviral infection
Primary MEF cultures were derived from E13.5 mouse
embryos and cultured in DMEM containing 10% fetal calf
serum as described previously (39). IMR-90 (American Type
Culture Collection) and Ecopack 2 293 cells (Clontech)
were cultured in DMEM (Invitrogen) supplemented with
Human Molecular Genetics, 2009, Vol. 18, No. 14 261910% FBS (Hyclone). Stable retroviral infections of IMR-90
(ATCC), C3H10T1/2 (ATCC) and MEFs were performed as
previously described (38). For sequential infections, cells
were infected with the second virus 2–3 days following the
initial infection. Selection with puromycin (1.5 mg/ml) or
geneticin (1 mg/ml) was done after all rounds of infection.
Senescence, transformation, tumor formation and
apoptosis assays
Staining for sa-b-galactosidase activity was performed as
described Lin et al. (29). Soft agar and focus formation
assays were performed as previously described (39). For
tumor formation assays, 8-week-old male nude mice
(Foxn1
nu Jackson Labs) were injected subcutaneously into
their shoulder ﬂank with 2   10
6 cells. Tumors were not
allowed to get . 2 cm in diameter as required by OHSU
IACUC guidelines.
For apoptosis assays, subconﬂuent cells were plated at 200
000 cells per 35 mm dish into growth media containing (10%
FBS) for 24 h. FGFR inhibitor PD173074 (Calbiochem) was
added at concentrations ranging from 1.25 to 10 mM (in
DMSO vehicle) in either 10% FBS medium or in medium
replaced to contain 0.1% FBS. PI3K inhibitor LY294002
(Cell Signaling Technology) and MEK inhibitor PD98059
(Calbiochem) were used at 50 mM. Cells were harvested 14 h
following addition of inhibitors and/or serum deprivation,
stained with annexin-5PE (BD) antibody and 7AAD (BD)
and ﬂow-sorted using FACS Caliber and De Novo FCS
Express V3 software.
Western blot and immunoﬂuorescence
For western blots, cells were lysed with RIPA buffer (50 mM
Tris–HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 1.0% NP-40,
0.5% sodium deoxycholate) containing COMPLETE Protease
Inhibitor cocktail (Roche). Equal amounts of protein were run
on 4–12% Novex Bis-Tris gels in MOPs buffer. Western blot-
ting was done as previously described (39) using the following
antibodies: c-Myc (N-262), BEK (C-17), p16 (M-156), p21
(sc-1207) ERK1 (K-23) and pERK (E-4) from Santa Cruz,
p53BP1 (S25) from Bethyl Labs, p53, p53-pS15, pChk2
(Thr68), Akt and pAkt from Cell Signaling Technologies
and p19
ARF, Chk2, Histone H3, phospho-Histone H3 (ser10)
and 53BP1 from Abcam and Trimethyl Histone H3 K9 from
Millipore. For immunoﬂourescence, cells were ﬁxed on cover-
slips and antibody staining performed as previously described
(52). Antibodies used for immunoﬂuorescence included gHis-
tone H2AX (pSer139) (Cell Signaling Technologies) pATM
(Ser1981) (Upstate) and p53BP1 (S25) (Bethyl Labs).
Cy3-conjugated Donkey Anti-Mouse (Jackson Immuno
Research) secondary antibody was used. DAPI staining was
used to visualize nuclei.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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